This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: British Columbia Cancer Agency Branch, Fundacio Clinic, Oslo University Hospital. Active years: 2012-2020.
Company Filing History:
2 out of 66 
2 out of 2 
2 out of 12 
Years Active: 2012-2020
Title: T Andrew Lister: Innovator in Lymphoma Research
Introduction
T Andrew Lister is a notable inventor based in London, GB, recognized for his contributions to the field of lymphoma research. He holds two patents that focus on methods for identifying, diagnosing, and predicting survival in lymphomas and lymphoproliferative disorders. His work has significant implications for improving patient outcomes through more accurate diagnostic techniques.
Latest Patents
Lister's latest patents revolve around the use of gene expression data to enhance the identification and diagnosis of lymphoproliferative disorders. His inventions include the Lymph Dx microarray, which is designed to obtain gene expression data from lymphoma samples. This technology allows for the development of more accurate predictors of survival and aids in determining the identity of specific lymphomas. The methods disclosed in his patents are instrumental in tailoring therapeutic approaches for patients diagnosed with these conditions.
Career Highlights
Throughout his career, Lister has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the University of Nebraska. His experience in these institutions has contributed to his expertise in lymphoma research and innovation.
Collaborations
Some of Lister's notable coworkers include George Wright and Bruce Tan, who have collaborated with him on various research projects. Their combined efforts have further advanced the understanding of lymphomas and the development of innovative diagnostic methods.
Conclusion
T Andrew Lister's work in lymphoma research exemplifies the impact of innovation in the medical field. His patents and collaborations have paved the way for more effective diagnostic tools, ultimately benefiting patients facing lymphoproliferative disorders.